Fig. 1From: Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertensionStudy population. We have chosen an a priori cut-off of 1500 days to differentiate short surviving patients from long surviving patients, to be close to the median survival found in the literatureBack to article page